Actinium Pharmaceuticals ATNM Stock
Actinium Pharmaceuticals Price Chart
Actinium Pharmaceuticals ATNM Financial and Trading Overview
| Actinium Pharmaceuticals stock price | 1.64 USD |
| Previous Close | 7.96 USD |
| Open | 7.95 USD |
| Bid | 7.6 USD x 800 |
| Ask | 0 USD x 800 |
| Day's Range | 7.61 - 8.07 USD |
| 52 Week Range | 4.73 - 15.12 USD |
| Volume | 321.88K USD |
| Avg. Volume | 198.49K USD |
| Market Cap | 204.41M USD |
| Beta (5Y Monthly) | 0.386619 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.47 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 31.8 USD |
ATNM Valuation Measures
| Enterprise Value | 124.76M USD |
| Trailing P/E | N/A |
| Forward P/E | -5.649635 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 2271.2427 |
| Price/Book (mrq) | 3.4817812 |
| Enterprise Value/Revenue | 1386.252 |
| Enterprise Value/EBITDA | -3.098 |
Trading Information
Actinium Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 0.386619 |
| 52-Week Change | 50.00% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 15.12 USD |
| 52 Week Low | 4.73 USD |
| 50-Day Moving Average | 8.67 USD |
| 200-Day Moving Average | 9.61 USD |
ATNM Share Statistics
| Avg. Volume (3 month) | 198.49K USD |
| Avg. Daily Volume (10-Days) | 176.53K USD |
| Shares Outstanding | 26.41M |
| Float | 25.7M |
| Short Ratio | 6.61 |
| % Held by Insiders | 2.25% |
| % Held by Institutions | 22.21% |
| Shares Short | 1.22M |
| Short % of Float | 4.62% |
| Short % of Shares Outstanding | 4.62% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:30 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -45026.66% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -28.68% |
| Return on Equity (ttm) | -61.76% |
Income Statement
| Revenue (ttm) | 90K USD |
| Revenue Per Share (ttm) | 0.004 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | 1.03M USD |
| EBITDA | -40272000 USD |
| Net Income Avi to Common (ttm) | -38925000 USD |
| Diluted EPS (ttm) | -1.55 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 94.52M USD |
| Total Cash Per Share (mrq) | 3.58 USD |
| Total Debt (mrq) | 2.46M USD |
| Total Debt/Equity (mrq) | 4.3 USD |
| Current Ratio (mrq) | 12.531 |
| Book Value Per Share (mrq) | 2.223 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -652000 USD |
| Levered Free Cash Flow (ttm) | -21811500 USD |
Profile of Actinium Pharmaceuticals
| Country | United States |
| State | NY |
| City | New York |
| Address | 275 Madison Avenue |
| ZIP | 10016 |
| Phone | 646 677 3870 |
| Website | https://www.actiniumpharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 49 |
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple targets in oncology and hematology, including CD45, CD33, HER3, and other. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company is based in New York, New York.
Q&A For Actinium Pharmaceuticals Stock
What is a current ATNM stock price?
Actinium Pharmaceuticals ATNM stock price today per share is 1.64 USD.
How to purchase Actinium Pharmaceuticals stock?
You can buy ATNM shares on the NYSE American exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Actinium Pharmaceuticals?
The stock symbol or ticker of Actinium Pharmaceuticals is ATNM.
Which industry does the Actinium Pharmaceuticals company belong to?
The Actinium Pharmaceuticals industry is Biotechnology.
How many shares does Actinium Pharmaceuticals have in circulation?
The max supply of Actinium Pharmaceuticals shares is 31.2M.
What is Actinium Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Actinium Pharmaceuticals PE Ratio is now.
What was Actinium Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Actinium Pharmaceuticals EPS is -1.47 USD over the trailing 12 months.
Which sector does the Actinium Pharmaceuticals company belong to?
The Actinium Pharmaceuticals sector is Healthcare.
Actinium Pharmaceuticals ATNM included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NYSE American Composite Index XAX | 5181.96 USD — |
+1.05
|
— — | 5114.35 USD — | 5190.51 USD — | — - | — — |
- {{ link.label }} {{link}}